Top 7 China Health AI & Medical AI Companies (2025)
China's health AI sector has emerged as a global powerhouse, leveraging massive medical datasets and advanced AI to transform healthcare delivery. In 2025, China has over 80 NMPA-approved AI medical devices in clinical use, more than any other country. From AI-powered CT lung cancer screening processing 1,000 scans daily in top hospitals to deep learning drug discovery reducing candidate identification timelines by 60 percent, Chinese health AI companies are at the forefront of medical innovation. The market is projected to reach CNY 80 billion by 2025, driven by government policy support and urgent demand for efficient healthcare in a population of 1.4 billion.
TL;DR
China has 80+ NMPA-approved AI medical devices, the most globally. Health AI market reaches CNY 80 billion in 2025. Top 7 companies: Yitu Healthcare, SenseTime Medical, Infervision, iFlytek Healthcare, Ping An Good Doctor, Tianjin Binhai AI Hospital, and Insilico Medicine.
Key Insights
Yitu Healthcare (依图医疗)
Leading medical AI company with chest CT and brain MRI analysis systems deployed in 300+ hospitals. AI assistant reduces radiologist reading time by 50 percent while maintaining 97 percent diagnostic accuracy for pulmonary nodule detection.
SenseTime Medical (商汤医疗)
Applies SenseTime's computer vision expertise to medical imaging with multi-organ CT/MRI analysis. Smart hospital platform integrates AI into entire clinical workflow from triage to surgical planning and post-operative monitoring.
Infervision (推想医疗)
Only Chinese medical AI company with regulatory approval in China, US, and EU. Chest CT AI system used in 400+ hospitals across 20+ countries. Pioneered AI-assisted COVID-19 diagnosis with 96 percent sensitivity.
iFlytek Healthcare (科大讯飞医疗)
Leverages NLP leadership for AI medical record processing, clinical decision support, and intelligent medical Q&A. AI system passed China's National Medical Licensing Examination with 96 percent score, enabling automated preliminary diagnosis.
Ping An Good Doctor (平安好医生)
China's largest online healthcare platform with AI-powered triage, diagnosis suggestions, and prescription management. AI system handles 90 percent of initial consultations autonomously, routing complex cases to human doctors.
Tianjin Binhai AI Hospital
Government-backed pilot hospital where AI manages scheduling, diagnosis, treatment planning, and follow-up. Uses multi-modal AI combining imaging, genomics, and clinical data for personalized treatment recommendations across oncology and chronic disease.
Insilico Medicine (英矽智能)
Pioneer in AI drug discovery with proprietary Chemistry42 and PandaOmics platforms. First company to advance an AI-designed drug (for idiopathic pulmonary fibrosis) from concept to Phase II clinical trials, reducing discovery timeline from 4 years to 18 months.
Side-by-Side Comparison
| Company | Focus Area | NMPA Approval | AI Tech | Hospital Reach | Global Expansion |
|---|---|---|---|---|---|
| Yitu Healthcare | Medical imaging | 4 products | CNN, attention | 300+ hospitals | Pilot in ASEAN |
| SenseTime Medical | Multi-organ imaging | 3 products | CV, multi-modal | 200+ hospitals | Middle East, APAC |
| Infervision | Chest CT, lung cancer | Triple certified | Deep learning | 400+ hospitals | 20+ countries |
| iFlytek Healthcare | NLP, CDS | 2 products | NLP, knowledge graph | 500+ hospitals | Limited |
| Ping An Good Doctor | Online consultation | Platform | NLP, triage AI | 450M users online | Southeast Asia |
| Binhai AI Hospital | Full hospital AI | Pilot program | Multi-modal AI | 1 hospital (flagship) | Pilot model |
| Insilico Medicine | Drug discovery | N/A (pharma) | Generative AI, RL | Clinical trials | Global clinical |
Frequently Asked Questions
As of 2025, China's NMPA has approved over 80 AI-based medical devices for clinical use, covering medical imaging, pathology, ECG analysis, and clinical decision support. This is the highest number of AI medical device approvals globally, reflecting China's aggressive regulatory pathway for medical AI products.
iFlytek Healthcare's AI system passed China's National Medical Licensing Examination with a score of 96 percent (the passing threshold is 60 percent). The system demonstrates proficiency across clinical knowledge, diagnosis reasoning, and treatment planning, enabling it to assist doctors with preliminary diagnosis and treatment suggestions.
AI drug discovery uses machine learning and generative AI to identify drug candidates, predict molecular properties, and optimize clinical trial design. Insilico Medicine (英矽智能) leads in China with 3 AI-designed drugs in clinical trials, having reduced typical drug discovery timelines from 4 years to 18 months using their proprietary platforms.
No. AI is designed to augment rather than replace doctors. In China, AI systems handle preliminary triage, assist with image interpretation, and provide decision support, but final diagnoses and treatment decisions remain with licensed physicians. AI reduces doctor workload by handling routine cases, allowing doctors to focus on complex and critical patients.
Chinese AI companies developed rapid diagnostic systems during COVID-19. Infervision's chest CT AI achieved 96 percent sensitivity for COVID detection. SenseTime's thermal imaging + facial recognition enabled automated fever screening at 10,000+ locations. AI-powered contact tracing systems were deployed across major cities for epidemic response.